New classification method for HPV-associated head and neck cancers
Source: www.techexplorist.com Author: Vidya Nagalwade Over the past few decades, the number of cases of head and neck squamous cell carcinoma (HNSCC) related to the human papillomavirus (HPV+) has risen significantly and is still rising. The human papillomavirus (HPV) has been linked to an increase in cancer of the throat and tonsils, which is projected to become the most common form of head and neck cancer by 2030. Identifying the right patients with HPV-related cancers is a major challenge in reducing treatment intensity. A new study identifies a subclass of HPV+ head and neck squamous cell carcinomas (HNSCC). It shows that treatment depends on the tumor type. The data show two distinct subtypes of HPV+ HNSCC, each with its features and treatment responses. The researchers examined data from 104 HPV+ HNSCC tumors and two publically available sources to find gene expression patterns that might reliably distinguish distinct tumor types. Among the 22 modules tested, one accurately classified HPV+ HNSCC tumors based on a different gene expression pattern. The NFKB classifier accurately predicted a favorable result in patients treated in the ECOG-ACRIN Cancer Research Group trial E1308, even with low-dosage radiation. Barbara Burtness, a Professor of Medicine at Yale School of Medicine, said, “This discovery opens new opportunities for treatment personalization, as we can now better understand the distinct requirements for tumor development in each subclass.” The findings have significant clinical implications. Clinicians treating HPV+ HNSCC are constantly looking for biomarkers that can be used to determine treatment intensity. The new [...]